News & Events
AUSTIN – Today, the Cancer Prevention and Research Institute of Texas (CPRIT) announced the appointment of Cindy WalkerPeach, Ph.D. as Chief Product Development Officer.
“Dr. WalkerPeach has extensive life science industry experience nationally and in Texas, bringing firsthand knowledge of translating promising research from the lab through clinical trials,” said CPRIT CEO Wayne Roberts. “Her familiarity with Texas’ needs and opportunities will have an immediate beneficial effect on the state’s cancer product development landscape.”
Kidney cancer is often detected too late to treat and historically survival rates are low. Fortunately, CPRIT has invested heavily into researching the causes behind kidney cancer and how to better treat it. As Director of the Kidney Cancer Program and Brugarolas Labs at The University of Texas Southwestern Medical Center, James Brugarolas, MD, PhD has been the recipient of 6 CPRIT Academic Research grants exceeding $5.5 million.
Yesterday I delivered CPRIT’s 2018 Annual Report to state leadership and the Texas Legislature. It can be accessed here on CPRIT’s new website.
This new website is a platform for sharing news and information on CPRIT’s investments and advances in cancer research, product development and prevention. The newsroom features our grantees and current CPRIT events, with access to our social media channels. New features include sections on CPRIT’s impact, greater detail on CPRIT Scholar recruitments and CPRIT-funded core facilities at Texas’ academic institutions. Also available are current reports used to inform the public, legislators and media.
With the 86th Texas Legislature in full swing, here is a summary of filed legislation concerning CPRIT. Please click on the links for more information.
House Joint Resolution 12 (Rep. John Zerwas) - Authorizes a second $3 billion in General Obligation Bonds for cancer research and prevention to be submitted to voters at the general election on November 5, 2019.
House Bill 39 (Rep. John Zerwas) - Removes restriction against new grant awards in FY 2023 in the event additional General Obligation Bonds are authorized by voters or another funding source is used for FY 2023 and beyond.
(AUSTIN) – Today, CPRIT leadership presented the agency’s legislative appropriations request (LAR) to the Senate Finance Committee. Among the highlights is the agency’s exceptional item request of $164 million in General Revenue to maintain grant program current services through FY 2021. Chief Executive Officer Wayne Roberts and Chief Operating Officer Heidi McConnell appeared before the committee to testify on behalf of CPRIT. See the presentation submitted to the committee.
AUSTIN — Today, four new CPRIT Scholar grants totaling $16 million were awarded. The grants will support the recruitment of investigators researching cancers of the brain and digestive system as well as experts in the field of immunotherapy.
“CPRIT Scholars are key to the momentum Texas has achieved in building a cancer-fighting ecosystem,” said Wayne Roberts, CPRIT CEO. “Attracting top talent to our state ensures that Texas institutions are at the cutting-edge of cancer research.”